Immix Biopharma, Inc.
NASDAQ:IMMX
Overview | Financials
Company Name | Immix Biopharma, Inc. |
Symbol | IMMX |
Currency | USD |
Price | 2.18 |
Market Cap | 59,966,649 |
Dividend Yield | 0% |
52-week-range | 1.26 - 7.46 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. |
Website | https://www.immixbio.com |
An error occurred while fetching data.
About Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD